H.C. Wainwright analyst Andrew Fein assumed coverage of Akero Therapeutics (AKRO) with a Buy rating and $72 price target Th firm says efruxifermin’s cirrhosis reversal and Phase 3 readouts support a bullish share view.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH Treatment
- Akero Therapeutics’ Phase 3 NASH Study: A Potential Game-Changer?
- Akero Therapeutics’ efruxifermin shows efficacy in Phase 2b MASH, fibrosis trial
- Strong Financial Position and Promising Clinical Developments Support Buy Rating for Akero Therapeutics
- Akero Therapeutics Advances in MASH Treatment Development